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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by incompletely
reversible airflow obstruction associated with inflammation in which monocytes/macrophages are
the predominant inflammatory cells. The only known genetic factor related to COPD is inherited
PiZZ deficiency of α1-antitrypsin (AAT), an inhibitor of serine proteases.
Methods: We investigated the basal and LPS-stimulated release of pro-inflammatory molecules
from blood monocytes isolated from age and gender matched healthy (n = 30) and COPD (n = 20)
individuals with and without AAT deficiency.
Results: After 18 h of cell culture the basal release of MMP-9 was 2.5-fold, p < 0.02 greater,
whereas IL-8 was 1.8-fold (p < 0.01) lower from COPD patient monocytes than from controls. LPS-
stimulated release of IL-6 and MCP-1 was greater from COPD patient's monocytes relative to
controls, while activation of control cells resulted in enhanced secretion of ICAM-1 and MMP-9
compared to COPD patients. Independent of disease status, monocytes from PiZZ AAT carriers
released less TNFα (by 2.3-fold, p < 0.03).
Conclusions: The basal and LPS-stimulated secretion of specific pro-inflammatory molecules from
circulating monocytes differs between healthy and COPD subjects. These findings may be valuable
for further studies on the mechanisms involved in recruitment and activation of inflammatory cells
in COPD.
Background
Chronic obstructive pulmonary disease (COPD) is a com-
plex disease caused by various genetic and environmental
risk factors acting singly or in concert. Severe alpha1-anti-
trypsin (AAT) deficiency, which results from a PiZZ geno-
type, is a well-known genetic risk factor associated with
the development of early onset COPD [1]. Although it has
been shown in a large number of AAT deficient individu-
als that smokers suffer more severe pulmonary impair-
ment at an early age compared to non-smokers [2], the
development of COPD in AAT deficient subjects, even
among current or ex-smokers, is not universal [3].
Tobacco smoking represents the most important environ-
mental risk factor for respiratory diseases and it is the first
risk factor for COPD [4,5]. However, only about 20% of
individuals who are smokers and have the normal PiMM
genotype of AAT will develop COPD [3]. These findings
lead to the idea that a combination of environmental
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factors, such as smoking, air pollution, childhood respira-
tory infections and latent adenoviral infections, and/or
genetic factors, such as AAT-deficiency, are likely the
essential contributors to the development of COPD.
Although inflammation has always been considered a
prominent feature in COPD, there is little work describing
the initiating events, regulatory mechanisms and subse-
quent underlying cellular and molecular processes that
lead to inflammation, tissue damage and remodeling in
COPD. Current studies show that neutrophils, eosi-
nophils, lymphocytes and macrophages are involved in
the inflammatory process of COPD [6]. Various inflam-
matory mediators derived from these inflammatory cells
are suggested to contribute to the chronic inflammation
and cause lung tissue damage [7]. Neutrophils are short-
lived cells that are recruited from the circulation to the air-
ways and are found in increased numbers in the airways
of smokers and patients with COPD [8]. Several studies
have demonstrated the differential roles of pro-inflamma-
tory mediators such as cytokines, chemokines, integrin
receptors and endothelial markers in controlling neu-
trophil sequestration and migration [9,10]. The neu-
trophil cell products have been shown directly to cause all
of the pathological features of COPD [11].
Monocyte recruitment to the lungs is also an important
step in COPD [6]. Monocytes release a variety of macro-
molecules and low molecular weight products that medi-
ate inflammation and repair. Expression of the genes for
these secretory products and induction of their release
depends on local signals in their microenvironment [12].
Different cytokines, chemokines and monocyte-specific
adhesion molecules are known to be involved in mono-
cyte activation, binding to stimulated endothelium and in
further migration within tissue. It has been reported that
in patients with COPD the migration of monocytes to
growth-related protein is significantly increased com-
pared to monocytes from healthy volunteers [13]. It was
also found that there are significantly higher levels of
monocyte chemoattractant protein-1 (MCP-1) and
growth-related protein in the sputum in COPD patients
compared to healthy volunteers and smokers [13].
Blood monocytes from the circulating pool migrate
through the blood vessel walls into various organs and
then differentiate into macrophages. Macrophages are the
predominant defence cell in the normal lung and are
increased during conditions associated with chronic
inflammation. For example, in bronchoalveolar-lavage of
patients with COPD, macrophage numbers are found to
be increased by 5 to 10 times [14]. Macrophages are sug-
gested to play a role in driving inflammatory process by
release of chemotactic factors and recruitment of neu-
trophils [15]. A more recent theory suggests that alveolar
macrophage-derived metalloproteinases mediate inflam-
mation by releasing TNF-α from macrophages with subse-
quent neutrophil influx, endothelial activation and tissue
breakdown caused by neutrophil derived proteinases
[16]. Unique mechanisms for leukocyte migration from
the bloodstream to the lung and activation have been pro-
posed based on the profile of the adhesion molecules,
cytokines and chemokines involved [17].
In this study we investigated pro-inflammatory molecular
release and expression of transcription factor NFκB by
blood monocytes isolated from individuals with COPD
and healthy controls with and without severe PiZZ
alpha1-antitrypsin (AAT) deficiency under basal condi-
tions and after stimulation with LPS. By using this experi-
mental approach we aimed to determine the differences
in pro-inflammatory molecular profile among monocytes
isolated from COPD patients and healthy controls, and
also to investigate if pro-inflammatory molecular release
is influenced by inherited deficiency of AAT.
Materials and methods
Subjects
The studied group consisted of 20 healthy PiMM AAT
adults (11 males and 9 females, aged 53 ± 9.6), 10 asym-
tomatic PiZZ AAT adults (5 males and 5 females, aged 53
± 9.6) and 20 COPD patients, among them 10 patients
with PiZZ AAT (5 males and 5 females, aged 47.4 ± 11)
and 10 patients with PiMM AAT (5 males and 5 females,
aged 59.4 ± 6.7). COPD was diagnosed according to the
NHLBI/WHO Workshop guidelines [18]. The PiZZ and
PiMM COPD patients had a forced expiratory volume in
one second (FEV1) ≤ 80% of that predicted and the FEV1/
Forced vital capacity ratio (FVC) ≤ 70%, while asympto-
matic PiZZ individuals had a FEV1 ≥ 80% and the FEV1/
FVC ratio ≥ 70%. All COPD patients included in the study
were in a stable, non-exacerbated phase of the disease. The
exclusion criteria were liver diseases, vasculitic or other
extra-pulmonary diseases. The control subjects showed no
evidence of any disease and had no respiratory symptoms;
none of them was on medication, and all had PiMM vari-
ant and normal plasma concentration of AAT. The PiZZ
individuals were recruited from the Swedish AAT Defi-
ciency Register. The PiMM COPD individuals were outpa-
tients at the Department of Respiratory Medicine,
University Hospital, Malmo. The healthy volunteers were
recruited from the hospital staff and their relatives. All the
individuals gave a signed, informed consent to take part in
this study, which has been approved by the research ethi-
cal committee of Lund University, Sweden. Patient charac-
teristics are given in Table 1.
Lung function tests
Lung-function tests included FEV1 and FVC. The measure-
ments were performed in accordance with EuropeanRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/11
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recommendations [19]. The results of FEV1 and FVC are
expressed as percent of predicted values according to Ber-
glund and co-workers [20]. The lung function tests were
performed after inhalation of bronchodilatator terbuta-
line (1 mg).
Isolation and culture of monocytes
Monocytes were isolated from the whole blood by the
Ficoll-Hypaque procedure as previously detailed [21].
Cell purity was > 95% as determined on an AC900EO
Auto Counter (Swelab Instruments, AB). Cell viability was
analysed by 0.4% trypan blue staining. Monocytes were
plated at a density of 4 × 106 cells/ml into plastic dishes.
After removal of non-adhering cells, the monocytes were
cultured in RPMI 1640 (Gibco, Life Technologies, Paisley,
Scotland) supplemented with 2 mM N-acetyl-L-alanyl-L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin,
1% nonessential amino acid, 2% sodium pyruvate and 20
mM Hepes (Fluka, Chemie AG) without serum at 37°C in
a 5%CO2. Monocytes were cultured alone or in the pres-
ence of lipopolisaccharide (LPS) 1 µg/ml for 18 h. Mini-
mum triplicate of repeats were undertaken for each
condition.
Assays of Inflammatory markers
Monocyte culture supernatants were analyzed to deter-
mine tumor necrosis factor-alpha (TNF-α), monocyte che-
moattractant protein (MCP-1), intracellular adhesion
molecule 1 (ICAM-1), human interleukin-1β (IL-1β), -6
(IL-6) and -8 (IL-8), gelatinase B (MMP-9) and sE-selectin
by using sandwich enzyme immunoassay kits (R&D Sys-
tems Europe Ltd, Abingdon, UK) according to the manu-
facturer's instructions. Absorbance was measured
spectrophotometrically at 450 nm using microplate
reader (Labsystems). The minimum detectable levels of
MMP-9 and sE-selectin were less than 0.156 ng/ml and
0,1 ng/ml, respectively.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts from monocytes were prepared exclu-
sively as described previously [22]. Electrophoretic mobil-
ity shift assay (EMSA) was used to detect the binding of
specific DNA sequence by NFκB p50 transcription factor
complexes. The Gelshift™ Kit for the detection of NFκB
p50 transcription factor was used (Geneka Biotechnology,
Inc, USA) according to the manufacturer's recommenda-
tions. The sequences of the double-stranded oligonucle-
otide probe are as follows: 5'-GCC-ATG-G GG-GGA-TCC-
CCG-AAG-TCC-3' and 3'-CGG-TAC-C CC-CCT-AGG-
GGC-TTC-AGG-5' (consensus binding sequence is under-
lined). Unlabeled competitor and mutant oligonucle-
otides were added in 50 × excess to confirm the specificity
of the binding reactions. In addition, rabbit polyclonal
antibody against NFκB was used in the competition reac-
tions to determine the specificity of the assay. In addition,
nuclear extracts were analyzed by using ELISA based NFκB
p65/NF B p50 transcription factor assay kit (Trans AM™,
Active Motif, Europe) according to manufactures instruc-
tions. Detection limit was <0.5 µg cell extract/well.
Table 1: Clinical characteristics of emphysema patients and control individuals with and without AAT-deficiency.
Subject group characteristics Control subjects M-AAT 
n= 20
Healthy subjects Z-AAT 
n = 10
COPD patients Z-AAT 
n = 10
COPD patients M-AAT 
n = 10
Male/Female 11/9 5/5 5/5 5/5
Age (years) 53 ± 9.6 47.4 ± 11 57 ± 12 59.4 ± 6.7
Smoking history:
Never smokers 9 6 3 0
Exsmokersa 10 3 6 8
Smokers b 1112
FEV1 % of predictedc 95.9 ± 17 94 ± 12 43 ± 13 37 ± 16
FVC % of predicted 92.8 ± 17 94 ± 14 63 ± 12 50 ± 15
FEV1/FVC% ratio 76 ± 8 77 ± 10 50 ± 15 40 ± 20
Medication
No medication 20 6 - -
Inhaled corticosteroids - 3 7 10
Bronchodilatators - - 10 8
Diuretics - - 3 3
Continuous oxygen - - 1 1
Anti-inflammatory - - - -
Anti-depressants - 1 - 1
a – exsmokers, stopped smoking at least 3 month before the study. b – current smokers. c – measured after bronchodilatation (terbutaline (1 mg)). 
Values are expressed as mean ± SD.Respiratory Research 2003, 4 http://respiratory-research.com/content/4/1/11
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Statistical analysis
Statistical analysis was performed with use of SPSS soft-
ware (version 11.0 for Windows, SPSS Inc. Chicago, USA).
The differences in measured parameters between study
groups were analyzed for their statistical significance with
the independent-samples two-sided t test and One-way
analysis of variance (ANOVA) combined with a multiple
comparison procedure (Scheffe multiple range test). Sig-
nificance was determined at the 5% level. Data are
expressed as median ± SD.
Results
In this study we investigated the release of pro-inflamma-
tory molecules from monocytes isolated from both PiZZ
AAT-deficiency and wild type PiMM-AAT groups of COPD
patients (n = 20) and in controls (n = 30) who were care-
fully sex-, age-, and AAT-phenotype matched. Care was
also taken to avoid confounding effects of smoking and
therefore only a minority of subjects analysed were cur-
rent smokers. The characteristics of the studied individu-
als are summarised in Table 1.
Release of Inflammatory molecular species from 
monocytes of COPD patients- vs controls
ELISA assays were performed on blood monocyte-condi-
tioned medium (18 h culture) to monitor secretion of
pro-inflammatory molecular species (Table 2). Mono-
cytes obtained from COPD patients, independent of AAT-
genotype, released greater amounts of MMP-9 (2.5-fold, p
< 0.028) but lower amounts of IL-8 (1.8-fold, p < 0.013)
compared to those obtained from controls. No significant
difference was observed in other measured molecules in
culture media from controls and COPD-monocytes
(Table 2). In separate experiments we measured secretion
of the same pro-inflammatory molecules from LPS-
exposed monocytes. After LPS-stimulation, monocytes
from COPD patients showed significantly greater release
of IL-6 (1.9-fold, p < 0.01) and MCP-1 (2.6-fold, p < 0.01)
than LPS-activated monocytes from control individuals
(Figure 1A). In contrast, ICAM-1 levels were higher in LPS-
activated monocytes (by 4.9-fold, p < 0.001) from control
individuals than from COPD patient-monocytes (Figure
1B). The up-regulation of other pro-inflammatory mark-
ers in LPS-stimulated monocytes was found to be of the
same magnitude in both groups (data not shown).
Release of inflammatory molecular species from 
monocytes isolated from PiZZ and PiMM AAT individuals
To evaluate whether AAT-genotype has any influence on
monocyte release of pro-inflammatory molecules, we
compared isolated monocytes from individuals with wild
type M and deficiency Z AAT, independent of disease
state. Monocytes isolated from M-AAT carriers were found
to release more TNFα (2.3-fold, p < 0.03) while the mean
levels of other measured molecules showed no significant
differences between Z-and M-AAT groups (Table 3). It
should be noted that exposure of Z-AAT monocytes to LPS
resulted in significantly greater release of IL-8 (3.3-fold, p
< 0.01) compared to M-AAT monocytes (data not shown).
NFκ-B activation in monocytes isolated from controls and 
COPD individuals
The expression and release of a variety of pro-inflamma-
tory molecules release are mediated by activation of tran-
scription factor NFκ-B [23]. We compared NF-κB
expression in COPD and healthy monocytes by using
both EMSA and ELISA based assays. As shown in figure 2,
NF-κB activity was increased by about 23.5% (not statisti-
cally significant) in monocytes from COPD patients com-
pared to monocytes from controls. Similarly, NF-κB
activity was found to be slightly, but not significantly (by
about 33%) higher in monocytes from Z-AAT than M-AAT
carriers.
Table 2: Comparison of Inflammatory biomarkers secreted by monocytes isolated from healthy individuals with or without COPD
Measured Biomarker COPD patients Healthy individuals Significance
Mean SD Mean SD P
MMP-9 (ng/ml) 7.6 3.6 2.99 0.9 0.028
IL-8 (pg/ml) 1.7 0.3 2.7 0.5 0.013
ICAM-1(ng/ml) 143 13 131 15 0.542
TNF-α (pg/ml) 9.7 2.9 10 3 0.75
MIF (pg/ml) 927 218 1314 214 0.246
IL-6 (pg/ml) 15 2 21 2 0.059
IL-1β (pg/ml) 3.4 1.1 6 3.1 0.249
MCP-1 (pg/ml) 425 116 452 123 0.736Respiratory Research 2003, 4 http://respiratory-research.com/content/4/1/11
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LPS-stimulated release of pro-inflammatory molecule from COPD patient monocytes relative to controls Figure 1
LPS-stimulated release of pro-inflammatory molecule from COPD patient monocytes relative to controls. Isolated blood 
monocytes from COPD patients (n = 20) and controls (n = 30) were activated with LPS (1 µg/ml) for 18 h. Pro-inflammatory 
molecular release was measured by ELISA methods. Monocytes from patients with COPD released greater levels of IL-6 and 
MCP-1, relative to controls (A), while the activation of control cells resulted in an enhanced secretion of ICAM-1 and MMP-9 
(B).Respiratory Research 2003, 4 http://respiratory-research.com/content/4/1/11
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Discussion
There is accumulating evidence that the mechanisms
involved in leukocyte recruitment to the lung are depend-
ent upon the stimulus and the site of migration. For exam-
ple, monocyte recruitment to mouse alveoli was found to
be dependent upon CD18 and intercellular adhesion
molecule-1 under basal conditions, but following bacte-
rial endotoxin stimulation, CD11a and vascular cell adhe-
sion molecule-1 were also involved, indicating a switch of
mechanism [16]. Release from circulating monocytes of
higher quantities of specific cytokines, chemokines and
MMPs may also contribute to cell migration. It has been
suggested that activated peripheral blood monocytes
more easily enter the lung and/or stimulate immune acti-
vation when present in the lung [24].
The concept that stable COPD is characterized by a sys-
temic inflammation is supported by reports showing
increased circulating levels of IL-6 and raised counts of
activated leukocytes [25]. To test the hypothesis that circu-
lating monocytes in stable COPD patients have enhanced
propensities to release certain pro-inflammatory mole-
cules, we designed a study in which we compared isolated
monocytes from COPD patients and controls. In addi-
tion, the influence of LPS-stimulation on pro-inflamma-
tory responses of these monocytes in vitro was studied.
Circulating monocyte activities could be influenced by
variations in patient characteristics, such as the degree of
lung function impairment, the presence of acute exacerba-
tions, cigarette smoking, and corticosteroid treatment. We
were careful to ensure that groups of individuals were well
matched in terms of these characteristics and that blood
was collected from patients when they were in a stable
clinical state. Therefore, we infer that the differences
observed in basal monocyte behaviour and in response to
LPS represent stable COPD.
Results from this study show that monocytes isolated
from COPD patients release significantly more MMP-9
but less IL-8 compared to controls. LPS-stimulation of
these cells results in a larger enhancement of IL-6 and
MCP-1 release from COPD-monocytes while monocytes
isolated from healthy individuals release higher levels of
ICAM-1. The in vivo significance of the observed variabil-
ity in monocyte release of specific pro-inflammatory mol-
ecules is not known, but basal differences between
monocytes isolated from control and COPD individuals
in the secretion of pro-inflammatory markers as well as
differences in release of specific molecules upon activa-
tion might be important parameters in the chronic
inflammatory processes in COPD.
Circulating monocytes generally are known to synthesise
significant amounts of MMPs, including matrilysin
(MMP-7), collagenase 1 (MMP-1) and gelatinase B
(MMP-9). Interestingly, expression of serine proteinases
and MMP-7 is suggested to be limited to a subset of "pro-
inflammatory" monocytes (15% of total) [26,27]. Most
MMPs are only expressed upon differentiation of mono-
cytes to macrophages and are not expressed, or are
expressed at nearly undetectable levels, in normal, healthy
tissues. In contrast, MMP expression is seen in any repair
or remodelling process in diseased or inflamed tissue, and
in essentially any cell type grown in culture. Although the
qualitative pattern and quantitative levels of MMPs vary
among cells, it is generally accepted that activated cells
express more MMPs. Our finding that monocytes isolated
from patients with stable COPD release more MMP-9
Monitoring of NFκB activation in monocytes from patients  with COPD and controls by ELISA-based TransAM kitAM Figure 2
Monitoring of NFκB activation in monocytes from patients 
with COPD and controls by ELISA-based TransAM kitAMCell 
nuclear extracts were prepared from monocytes isolated 
from COPD patients and controls with and without PiZZ 
AAT deficiency. NFκB activity assay was performed in a 96-
well plates with 10 µg of cell extract per well. Absorbance 
was measured by spectrophotometry at 405 nm. A positive 
control performed by using a nuclear extract derived from 
Jurkat cells. This extract is optimized to give a strong signal 
when used at 2.5 µg/well. Specificity controls were per-
formed by adding a molar excess (20 pmol/well] of mutant 
NFκB oligonucleotide [the positive signal remained unaf-
fected] and wild-type NFκB oligonucleotide (a signal was 
abolished). The bars represent mean values of three inde-
pendent measurements ± SD.
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favours recent theory supporting the potential role of high
levels of MMPs (including MMP-9) in amplifying inflam-
mation in COPD. MMP-9 has also been shown to be
markedly over-expressed by alveolar macrophages from
patients with COPD [28].
IL-8, a selective chemoattractant of neutrophils that may
be secreted by macrophages, neutrophils, and airway epi-
thelial cells, is present at high concentrations in induced
sputum and BAL fluid of patients with COPD [29]. IL-8
may play a primary role in the activation of both neu-
trophils and eosinophils in the airways of COPD patients
and may serve as a marker in evaluating the severity of air-
way inflammation [30]. It was also reported that IL-8 is
released from active monocytes and induces neutrophil
and basophil chemotaxis [29,31]. We found that mono-
cytes isolated from COPD patients release significantly
less IL-8 than monocytes from control subjects. These
results lead to the conclusion that chemotactic activity of
circulating monocytes in COPD patients in the stable clin-
ical state is not increased, but rather suppressed. Although
it has been found that high doses of corticosteroids can-
not reduce the inflammatory response, concentrations of
IL-8, or proteases in the sputum of the patients with
COPD [32], observed lower release of IL-8 from COPD
patient blood monocytes might be related to corticoster-
oid treatment. We also find that the LPS-activated COPD
monocytes release more IL-6 and MCP-1 and less ICAM-1
than monocytes isolated from healthy individuals. The
significance of these differences in IL-8, IL-6 and MCP-1
release by monocytes from COPD and healthy subjects
remains to be determined, but may arise from different
mechanisms dependent on the basal status of monocytes.
We compared levels of pro-inflammatory molecules
released by monocytes obtained from PiZZ and PiMM
AAT individuals independent of disease status. Our results
show that M-AAT monocytes release significantly more
only TNFα, while LPS-activation results in a larger release
of IL-8 from Z-AAT compared to M-AAT monocytes. The
profile of release of other measured molecules was similar
for both subject groups. Our findings that LPS-activation
of monocytes isolated from PiZZ AAT results in a larger
release of IL-8 suggest that these monocytes might have
higher chemoattractant activity than those isolated from
PiMM AAT individuals. Recently it has been reported that
chemotactic activity from COPD patient sputum of AAT-
deficiency is increased compared to matched control
patients with COPD [33].
The genes for a number of cytokines involved in airway
inflammation in COPD are regulated by nuclear factor-κB
(NF  κB), which in non-stimulated cells is localised in
cytoplasm but upon stimulation translocates into the
nucleus and binds to specific κB elements in the promoter
of target genes [34]. In this study we evaluated whether
NFκB expression is modified in monocytes isolated from
stable COPD patients compared to controls. Although no
statistically significant difference was found in NFκB
expression between the groups analyzed, monocytes iso-
lated from COPD patients showed consistently higher
NFκB activation (by about 22.5%) than controls. In addi-
tion, monocytes isolated from PiZZ AAT carriers, com-
pared to PiMM-AAT, also showed higher levels of NFκB
(by 33%). These findings suggest that NFκB might be
involved in the activation of circulating monocytes in
COPD patients, particularly with severe PiZZ AAT
deficiency.
Conclusions
Although further clinical studies are necessary to deter-
mine the significance and factors influencing the phe-
nomena described here, this study represents the first
attempt to compare the pro-inflammatory properties of
circulating monocytes isolated from stable COPD patients
and controls. Pro-inflammatory molecules, such as endo-
Table 3: Comparison of Inflammatory biomarkers secreted by monocytes isolated from individuals with and without severe PiZZ AAT-
deficiency
Measured Biomarker PiMM PiZZ Significance
Mean SD Mean SD P
MMP-9 (ng/ml) 5 1.9 4.4 1 0.3
MCP-1 (pg/ml) 498 124 348 95 0.06
ICAM-1(ng/ml) 130 13 145 14 0.45
TNF-α (pg/ml) 12.8 9 5.7 2.5 0.029
MIF (pg/ml) 1315 192 1179 264 0.34
IL-6 (pg/ml) 18 1.9 18.4 3 0.414
IL-1β (pg/ml) 5.9 3 3 0.9 0.14
IL-8 (pg/ml) 2.2 0.4 2.5 0.47 0.843Respiratory Research 2003, 4 http://respiratory-research.com/content/4/1/11
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toxin and lipopolysaccharide (LPS), are known to play a
role in the up-regulating inflammation [35]. However,
other factors such as cellular migration, infiltration and
activation state, specific cytokines and chemokines, and
the initiation and regulatory mechanisms are likely to
play major roles COPD pathology. Our findings that cir-
culating monocytes isolated from COPD patients show a
profile of released pro-inflammatory molecules and
response to LPS stimulus distinct from control monocytes
offer a guide to future investigation of the complex mech-
anisms involved in chronic inflammation in COPD.
Abbreviations
AAT, alpha-1-antitrypsin; PiZZ, homozygous AAT-defi-
ciency variant; PiMM, wilde type AAT variant; COPD,
chronic obstructive pulmonary disease; MMP, matrix met-
alloproteinase; MCP, monocyte chemoattractant protein;
CRP, C-reactive protein; FEV1, forced expiratory volume in
1 second; FVC, forced vital capacity; ACE, angiotensin
converting enzyme; LPS, lipopolysaccharide.
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